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Three-Dimensional Structures of PDE4D
in Complex with Roliprams and Implication
on Inhibitor Selectivity
7, and 8 prefer to hydrolyze cAMP, while PDE5, 6, and
9 are cGMP specific. PDE1, 2, 3, 10, and 11 take both
cAMP and cGMP as their substrates. In the past three
decades, selective inhibitors against the different PDE
families have been widely studied as cardiotonic agents,
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Chapel Hill, North Carolina 27599 vasodilators, smooth muscle relaxants, antidepres-
sants, antithrombotic compounds, antiasthma com-
pounds, and agents for improving cognitive functions
such as memory (Reilly and Mohler, 2001; Rotella, 2002;Summary
Giembycz, 2000; Souness et al., 2000; Huang et al.,
2001). For example, the PDE5 inhibitor sildenafil (Viagra;Selective inhibitors against the 11 families of cyclic
Figure 1) is a drug for male erectile dysfunction, and thenucleotide phosphodiesterases (PDEs) are used to
PDE3 inhibitor cilostamide is a drug for heart diseases.treat various human diseases. How the inhibitors se-
Selective inhibitors of PDE4 form the largest group oflectively bind the conserved PDE catalytic domains is
inhibitors for any PDE family and have been studied asunknown. The crystal structures of the PDE4D2 cata-
anti-inflammatory drugs targeting asthma and chroniclytic domain in complex with (R)- or (R,S)-rolipram sug-
obstructive pulmonary disease (COPD) and also as ther-gest that inhibitor selectivity is determined by the
apeutic agents for rheumatoid arthritis, multiple sclero-chemical nature of amino acids and subtle conforma-
sis, type II diabetes, septic shock, atopic dermatitis,tional changes of the binding pockets. The conforma-
and other autoimmune diseases (Giembycz, 2000; 2002;tional states of Gln369 in PDE4D2 may play a key role
Souness et al., 2000; Huang et al., 2001; Piaz and Gio-in inhibitor recognition. The corresponding Y329S mu-
vannoni, 2000; Barnette and Underwood, 2000; Sturtontation in PDE7 may lead to loss of the hydrogen bonds
and Fitzgerald, 2002). The PDE4 selective inhibitor roli-between rolipram and Gln369 and is thus a possible
pram (Figure 1) was studied as an antidepressant andreason explaining PDE7’s insensitivity to rolipram inhi-
has been used to classify the PDE families (Bobon etbition. Docking of the PDE5 inhibitor sildenafil into
al., 1988; Scott et al., 1991). How selective inhibitorsthe PDE4 catalytic pocket further helps understand
with different chemical structures (Figure 1) bind to theinhibitor selectivity.
similar catalytic pockets of PDEs is unknown. Herein,
we report the crystal structures of the catalytic domain
Introduction of human PDE4D2 (the second splicing species in the
PDE4D subfamily) in complex with (R)- or (R,S)-rolipram
Cyclic nucleotide phosphodiesterase (PDE) hydrolyzes (Table 1). These structures reveal the selective binding
adenosine or guanosine 3,5-cyclic monophosphate of roliprams to PDE4. The sequence alignment shows
(cAMP or cGMP) to 5-AMP or 5-GMP (Torphy, 1998; a conserved variation of the rolipram binding residues
Conti and Jin, 1999; Soderling and Beavo, 2000). Cyclic across the PDE families, suggesting that the inhibitor
AMP and cyclic GMP are intracellular second messen- selectivity is determined by the chemical nature of amino
gers, mediating the response of cells to a wide variety of acids and the conformational variation of the binding
hormones and neurotransmitters in signal transduction pockets.
pathways. Regulation of cAMP and cGMP concentration
in vivo is an essential step for many metabolic pro-
cesses, such as cardiac and smooth muscle contrac- Results and Discussion
tion, glycogenolysis, platelet aggregation, secretion, li-
polysis, learning, ion channel conductance, apoptosis, Architecture of the PDE4D-Rolipram Structure
and growth control (Houslay and Milligan, 1997; Hous- Four molecules of the catalytic domain of PDE4D2 with
lay, 1998; Antoni, 2000). amino acids 79–438 are associated into a tetramer in
To date, 11 families and 21 genes of PDEs have been the crystallographic asymmetric unit (Figure 2). The
reported (Torphy, 1998. Houslay and Milligan, 1997; Cor- monomeric PDE4D2 molecule contains 16 helices and
bin and Francis, 1999; Houslay et al., 1998; Manganiello has the same folding as PDE4B, except for the random
et al., 1995; Mehats et al., 2002; Mu¨ller et al., 1996; loop of residues 422–434 in PDE4D2 that corresponds
Thompson, 1991; Zhao et al., 1997). The mRNAs of the to helix H17 in PDE4B (Xu et al., 2000). A superposition
PDE genes are subject to alternative splicing, resulting of the catalytic domain of (R)-rolipram-bound PDE4D2
in over 60 PDE isoforms in various human tissues. The over unligated PDE4B shows an rms deviation of 0.57 A˚
molecules of all PDE families contain a conserved cata- for Catoms, indicating the structural similarity between
lytic domain of about 300 amino acids with an approxi- the PDE4 subfamilies and also implying no dramatic
mate 25% sequence homology. However, each PDE overall conformational changes upon binding of (R)-roli-
family recognizes a specific substrate and possesses pram (Figure 3). However, substantial changes are ob-
its own selective inhibitors. Thus, the families of PDE4, served for several loops. The most significant movement
is the Met357 loop, which showed 2–3 times the average
deviation. Since Met357 forms van der Waals interac-*Correspondence: hke@med.unc.edu
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Figure 1. Chemical Structures of the PDE In-
hibitors
Rolipram, cilomilast, and CP-293,121 are
PDE4 selective inhibitors. Zardavarine is a
dual inhibitor of PDE3 and PDE4. Cilostamide
is a PDE3 selective inhibitor. Sildenafil is a
PDE5 selective inhibitor.
tions with (R)- and (S)-roliprams, the conformational 0.55 M, respectively (Dr. Wei Zhang, personal commu-
nication). The crystal structures showed that the (R)-change of this loop is likely the consequence of rolipram
binding. and (S)-enantiomers of rolipram bind to the active site
of PDE4D2 with similar orientations and interact with theIn spite of the tetrameric form in our crystals, a PDE4D
dimer was proposed as the active catalytic form of the same residues (Figure 4). Roliprams form two hydrogen
bonds with the side chain of Gln369 and numerous hy-enzyme on the basis of the crystal structure of the PDE4D
catalytic domain in complex with zardavarine (Lee et al., drophobic interactions with the active site residues. The
cyclopentyloxy groups of (R)- and (S)-roliprams sit in a2002). This argument is supported by the fact that a
dimer is observed in a different crystal form of PDE4D2 hydrophobic pocket, interacting with residues Ile336,
Met337, Phe340, Met357, Ser368, Gln369, and Phe372.that was grown in the presence of 0.1 M calcium and 1
mM (R)-rolipram (our unpublished data) and that the The phenylmethoxy rings of (R)- and (S)-roliprams stack
over Phe372 and also contact Tyr159, Asn321, Tyr329,molecular sieving column in the protein purification
showed a peak with an apparent molecular mass of 75 Thr333, Ile336, and Gln369 via van der Waals forces.
Although the pyrrolidone groups of (R)- and (S)-roli-kDa that is equivalent to a dimer of the catalytic domain
of PDE4D2. However, the PDE4B domain with amino prams have an opposite chirality, they unexpectedly
interact with the same residues of PDE4D2. Surprisingly,acids 152–528 that retains catalytic activity is a mono-
mer in crystals (Xu et al., 2000; Rocque et al., 1997), and the pyrrolidone rings, which are anchored in the direc-
tion of the metal binding pocket, form no hydrogenthe PDE4A catalytic domain in the various oligomeriza-
tion states from monomer to tetramer is active (Lario et bonds with the active site residues or divalent metals,
but form polar interactions with His160, Met273, Leu319,al., 2001). Thus, the crystallographic and biochemical
studies suggest that either monomer, dimer, or tetramer Phe340, and Phe372. The interactions of (R)- and
(S)-roliprams with the active site residues in the crystalmay be catalytically active, depending on the isoforms
of the enzyme. structure agree qualitatively with, but are somewhat dif-
ferent in detail from, the prediction of rolipram binding
in the docked model (Dym et al., 2002). Comparison ofRolipram Binding
The (R)- and (R,S)-roliprams bind to the catalytic domain (R)-rolipram binding with the docked model of cAMP
(Xu et al., 2000) shows overlap of the phenylmethoxyof the recombinant PDE4D2 with IC50 values of 0.33 and
Structures of the PDE4D2-Rolipram Complexes
867
Table 1. Statistics on Diffraction Data and Structure Refinement of PDE4D Inhibitors
Data Collection
(R,S)-Rolipram (R)-Rolipram
Space group P212121 P212121
Unit cell (a, b, c) (A˚) 99.8, 111.5, 160.0 99.3, 112.5, 160.9
Resolution (A˚) 2.0 2.3
Total measurements 677,028 491,376
Unique reflections 89,779 77,976
Completeness (%) 86.7 (69.1)a 97.0 (75.6)
Average I/ 20.0 (3.8) 14.0 (2.8)
Rmerge 0.065 (0.54) 0.053 (0.246)
Structure Refinement
R factor 0.233 0.224
Rfree 0.266 (7.4%) 0.260 (9.5%)
Resolution 50–2.0 A˚ 50–2.3
Reflections 89,775 75,736
RMS deviation
Bond (A˚) 0.0061 0.0062
Angle () 1.21 1.19
Average B factor (A˚2)
All atoms 41.8 38.5
Protein 41.9 38.7
Inhibitor 48.8 37.2
Zn1 35.0 32.3
Zn2 62.0 62.6
Water 32.7 27.1
a The numbers in parentheses are for the highest resolution shell.
group of (R)-rolipram over adenosine of cAMP. This is Recently, the crystal structure of the catalytic domain
of PDE4D in complex with the inhibitor zardavarine hasconsistent with the earlier prediction of Kleinman et al.
(1998) on the basis of structure-activity relationships of been reported (Lee et al., 2002). Zardavarine binds to
the same hydrophobic pocket as rolipram and interactsthe hydroxamate-containing inhibitor CP-293121.
The small contribution of the pyrrolidone ring to roli- with residues Tyr159, Met273, Leu319, Ile336, Met337,
Phe340, Met357, Gln369, and Phe372 (PDE4D2 number-pram binding as observed in our crystal structure pre-
dicts a similar affinity of (R)- and (S)-roliprams to the ing). It forms hydrogen bonds with Gln369 and Tyr159
but does not directly interact with the metals. The crystalPDE4 family. However, the results from the biochemical
study are controversial. One group reported that (R)- structures of PDE4D in complex with rolipram and zarda-
varine suggest that all the PDE4 inhibitors, whether theyand (S)-roliprams show no observable differences in
binding affinity and inhibition of cAMP hydrolysis be- have similar or different chemical structures, would
share a similar set of binding residues, although thetween the four subfamilies of PDE4 (Demnitz et al., 1998).
In contrast, the results from other groups showed that detailed interactions or partnership may vary from inhibi-
tor to inhibitor. Since zardavarine is a dual inhibitor of(R)-rolipram has 10- to 20-fold tighter binding and 3- to
10-fold more inhibition of cAMP hydrolysis than PDE3 and PDE4 (Underwood et al., 1994), the informa-
tion on the binding pocket as revealed in the PDE4D-(S)-rolipram (Torphy et al., 1992; Barnette et al., 1996;
Laliberte et al., 2000). The reason for the differing results inhibitor structures might be useful for the design of
inhibitors against other PDE families.is not clear. One possibility might be the fluctuation of
the molecular conformation of PDE4 in solution, which
may depend on protein preparation under certain chemi- Implications on Inhibitor Selectivity
The sequence homology suggests that the PDE familiescal environments, such as metal ion concentration in
solution. The metal dependence of rolipram affinity was share a similar three-dimensional structure in their cata-
lytic domains. However, each of the PDE families pos-reported, as shown by the case that the 12-fold stereo-
selectivity of (R)-rolipram over (S)-rolipram in the holoen- sesses its own selective inhibitors. Thus, the questions
about inhibitor selectivity remain puzzling. How do thezyme of PDE4A (the enzyme with the divalent metals)
was reduced to about 2-fold in the apoenzyme (the en- selective inhibitors for the different PDE families prefera-
bly bind one family of catalytic pockets among manyzyme without metals; Liu et al., 2001). Our preliminary
study on the different crystal form grown in the presence of apparently similar shapes and sizes? How do PDE4
inhibitors with different chemical structures bind to theof 0.1 M CaCl2 showed an extra peak, which was tenta-
tively interpreted as a calcium ion and interacted with same pocket? What are the determinants for PDE inhibi-
tor selectivity? The structure of PDE4D2 complexed withthe two metals and pyrrolidone (our unpublished data).
Thus, the additional interactions of the peak with pyrroli- rolipram provides insight into the selective binding of
PDE4 inhibitors and also sheds light on the inhibitordone might account for the high affinity of rolipram in
the presence of metal (Liu et al., 2001). selectivity among the PDE families.
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868
In terms of the geometric shape, the active sites of
the PDE families can be further divided into four sub-
pockets, respectively, for binding of divalent metals and
three groups (cyclopentyloxy, phenylmethoxy, and pyr-
rolidone) of rolipram. The metal binding subpocket in-
cludes four metal binding residues (His164, His200,
Asp201, and Asp318) and His160, which is presumably
a key residue for the cAMP hydrolysis. These five resi-
dues are identical across the PDE families (Figure 4),
implying a common mechanism of the binuclear cataly-
sis for all PDEs. The subpocket for the cyclopentyloxy
group of rolipram is made up of characteristic hydropho-
bic residues Met337, Phe340, and Met357, and may
therefore accommodate a hydrophobic substitution
group with a size comparable to cyclopentane. The sub-
pocket for the phenylmethoxy group of rolipram has a
“ditch”-like shape, with Ile336 and Phe372 sitting on
each side. Thus, for the design of new PDE4 inhibitors,
modification of the phenyl group of rolipram may be
limited to a planar ring to fit the ditch. In addition, the
methoxy of the phenylmethoxy group occupies an open-
ing space made up of Asn321, Tyr329, Trp332, Thr333,
and Gln369. This opening space is apparently bigger
than the methoxy group and therefore could accept a
larger group containing either polar or nonpolar atoms.
In fact, the difluoromethoxy group of zardavarine occu-
pies the pocket and forms hydrogen bonds with Gln369
(Lee et al., 2002). The subpocket for the pyrrolidone
group of rolipram is adjacent to the metal pocket and
also open to the surface of the molecule. Thus, dramatic
modifications on pyrrolidone could be performed to
make interactions with either metals or the residues near
the active site for tighter binding and better selectivity
against different families of PDEs. Since the cyclopenty-
loxy and phenylmethoxy groups of cilomilast and CP-
293121 are common to rolipram (Figure 1), the binding
of these groups is expected to be the same as that of
rolipram. The remaining groups of cilomilast and CP-
293121 are expected to occupy the pyrrolidone sub-
pocket of rolipram and to extend their interactions with
the metal ions or nearby residues, thus accounting for
their high affinity for PDE4.
In addition, the structure-based sequence alignment
of the rolipram binding residues provides insight into
inhibitor selectivity (Figure 4). Gln369 is the only rolipram
binding residue absolutely conserved in all the PDE fam-
ilies. Since hydrogen bonds are major factors for de-
termining the accurate orientation of a ligand, Gln369
and its conformation must play a key role in inhibitor
binding and selectivity. Hydrophobic residues Tyr159,
Met273, Leu319, Trp332, Ile336, Phe340, Met357, and
Phe372 are conservatively substituted in other families
of PDE (Figure 4). These residues contribute the hy-
drophobic interactions to the binding of inhibitors, and
their important roles are confirmed by the mutagenesis
data (Richter et al., 2001; Atienza et al., 1999). The varia-Figure 2. The Catalytic Domain of PDE4D2
tion of these residues will determine the size and shape(A) Ribbon diagram of the monomeric PDE4D2 catalytic domain.
Rolipram, pink balls; two divalent metals, green balls. of the binding pockets in different PDE families, thus
(B) Surface presentation of the monomeric PDE4D2 catalytic domain. defining inhibitor selectivity. Asn321, Tyr329, and
Rolipram, yellow noodle. Ser368 are three residues showing the largest variation
(C) Ribbons presentation of the tetramer of the PDE4D2 catalytic across the PDE families (Figure 4) and must play criticaldomain.
roles in defining inhibitor selectivity. In short, we specu-
late that the inhibitor selectivity must be determined
Structures of the PDE4D2-Rolipram Complexes
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Figure 3. Stereo View of Superposition be-
tween the Catalytic Domains of PDE4D (Yel-
low) and PDE4B (Red)
(R)-Rolipram is shown in CPK model.
by a combination of different amino acids and subtle absolutely conserved across PDE families, may serve
as a scaffold to support formation of the hydrogen bondsconformational changes at the active site of each PDE
family. between Gln369 and rolipram (Figure 6). We speculate
that the hydrogen bonding network of Tyr329-Gln369-
rolipram must play a key role in the recognition of theDocking of Sildenafil into the Active Site of PDE4D
To investigate inhibitor selectivity, we modeled the inhibitors. The potential loss of the hydrogen bond be-
tween Tyr329 and Gln369 by the mutation of tyrosinePDE5 selective inhibitor sildenafil (Figure 1), a drug for
treatment of male erectile dysfunction, into the catalytic to serine in PDE7 is thus expected to dramatically
change the side chain conformation of Gln369 in orderpocket of PDE4D2 (Figure 5). Sildenafil selectively binds
PDE5 with an IC50 value of about 3.5 nM, in comparison to form a hydrogen bond with Ser373 in PDE7 (Figure
6). As a result, the hydrogen bonds between rolipramwith an IC50 of 7.7 M for the binding to PDE4 (Corbin
and Francis, 2002). The model shows an overall fit of and Gln369 in PDE4 may be absent in PDE7, to diminish
the rolipram inhibition in PDE7.sildenafil into the catalytic pocket of PDE4. The purine-
like ring of sildenafil sits in the hydrophobic pocket and
stacks against Phe372, whereas Gln369 forms a hydro- Biological Implications
Eleven families of human PDEs in different human tis-gen bond with the oxygen of the purine-like ring. In
addition, two oxygen atoms of the sulfonamide group of sues are involved in regulation of cAMP and cGMP con-
centrations in various biological processes. Each familysildenafil directly contact the divalent metals via charge-
charge interactions. However, the side chain of Asn321 of PDEs possesses its own selective inhibitors that bind
to the conserved catalytic domains. It has remainedshows a distance as short as 2 A˚ to several atoms of
the purine-like ring in the model. Thus, the native amino a mystery how the inhibitors with different structures
selectively inhibit the similar catalytic pocket of PDEs.acid alanine in PDE5, which corresponds to Asn321, is
expected to avoid the collisions and to favor hydropho- The crystal structures of PDE4D2 in complex with (R)-
or (R,S)-rolipram reveal the detailed binding of the inhibi-bic interactions with the purine-like ring of sildenafil.
Since Asn321 dramatically varies across the PDE fami- tors. The sequence alignment of the rolipram binding
residues shows that the majority of the residues are welllies (Figure 4), a critical role for this residue in inhibitor
selectivity is proposed. This argument is supported by conserved. Among them, Gln369 is the only identical
residue in the PDE families and forms hydrogen bondsthe results that the same Asn to Ala replacement in
PDE6 and PDE11 also shows the high sildenafil selectiv- with rolipram. Therefore, the conformational state of
Gln369 will be critical for binding of the inhibitors andity (Corbin and Francis, 2002).
differentiating inhibitor selectivity. Since PDE7 contains
serine in the corresponding position of Tyr329, Gln369Insensitivity of PDE7 to Rolipram Inhibition
Like PDE4, PDE7 is highly cAMP specific, but rolipram might loose the capability of forming hydrogen bonds
with rolipram because of the possible loss of the sup-insensitive. Thus, to further investigate inhibitor selectiv-
ity, we modeled the catalytic pocket of PDE7. Sequence porting hydrogen bond between Tyr329 and Gln369.
This may be a reason to account for the insensitivity ofalignment of PDE4 and PDE7 showed that 6 out of 14
rolipram binding residues are identical between the two PDE7 to rolipram inhibition. Asn321 is a residue that
changes dramatically across the PDE families and mayfamilies, whereas the remaining 8 residues are conser-
vatively mutated (Figure 4). A careful examination of the play a critical role in the recognition of inhibitors. To
investigate inhibitor selectivity, we docked the PDE5PDE4D-rolipram structure suggests that the replace-
ment of corresponding Tyr329 with serine in PDE7 might selective inhibitor silnadefil into the active site of
PDE4D2. Overall, sildenafil fits the pocket, but severalbe the key to switch the highly specific binding of roli-
pram in PDE4 to no binding in PDE7. The hydrogen atoms of the purine-like ring show a distance as short
as 2 A˚ to the side chain of Asn321. Correspondencebond of Tyr329 with Gln369, which is the only residue
Structure
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Figure 4. Binding of (R)- and (S)-Roliprams
(A) Stereo view of the electron density for (R)-rolipram. The omitted (2Fo  Fc) map was contoured at 1.5 .
(B) Stereo view of the electron density for (R,S)-rolipram. (R)-rolipram, yellow sticks; (S)-rolipram, orange.
(C) Rolipram binding at the catalytic pocket of PDE4D2. Zinc coordinates with His164, His200, Asp201, and Asp318 (purple). The second
metal (Me2) is tentatively interpreted as magnesium and binds to Asp318 and a water molecule. (R)- and (S)-roliprams bind to the hydrophobic
pocket in very similar orientations and interact with the same residues of PDE4. They form hydrogen bonds only with Gln369 but do not
directly interact with the divalent metals.
(D) Sequence alignment of the rolipram binding residues between 11 PDE families. The metal binding residues are marked with asterisks.
Most of the rolipram binding residues are conserved, but not identically, implying their key roles in defining of inhibitor selectivity.
Structures of the PDE4D2-Rolipram Complexes
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Figure 5. Model of PDE5 Selective Inhibitor Sildenafil (Viagra)
Bound in the Catalytic Pocket of PDE4D2
Overall, sildenafil fits in the pocket, but several atoms of the purine-
like ring of sildenafil are located at a distance as short as 2 A˚ from
the side chain of Asn321. The correspondence of alanine to Asn321
in PDE5, 6, and 11 is expected to favor hydrophobic interactions,
thus possibly explaining their high selectivity.
of alanine to Asn321 in PDE5, 6, and 11 might favor
hydrophobic interactions between the inhibitor and the
proteins, thus explaining the high sildenafil selectivity
of these proteins. In summary, our work suggests that
inhibitor selectivity is defined by both the chemical na-
ture of amino acids and the conformational variation of
the binding pockets.
Figure 6. A Model for Insensitivity of PDE7 to Rolipram Inhibition
(A) The hydrogen bonds (dotted lines) between Gln369 and rolipramExperiment Procedures
in PDE4.
(B) The correspondence of residues Ser373, Ser377, and Gln413 inProtein Expression and Purification
PDE7A to Tyr329, Thr333, and Gln369 in PDE4D2 may lead Gln413The EST (expressed sequence tag) cDNA clones of PDE4D2
to adopt a new conformation to form a hydrogen bond with Ser377.(BF059733) were purchased from ATCC and subcloned by standard
As a result, Gln413 would not be capable of forming hydrogen bondsmethods. The coding regions for amino acids 79–438 of PDE4D2
with rolipram. The orange sticks mark the side chain conformationwere amplified by PCR and subcloned into the expression vector
of Gln369 in PDE4.pET15b. The resulting plasmid pET-PDE4D2 was transformed into
E. coli strain BL21 (Codonplus) for overexpression. The E. coli cell
carrying pET-PDE4D2 was grown in LB medium at 37C to the ab-
sorption A600  0.7, and then 0.1 mM isopropyl -D-thiogalactopy- Laboratory (Table 1). The catalytic domain of PDE4D2 (amino acids
79–438) in complex with racemic (R, S)-rolipram was crystallizedranoside was added for further growth at 12C for 40 hr. The recom-
binant PDE4D2 was purified by Ni-NTA affinity column (Qiagen), against a well buffer of 0.05 M HEPES (pH 7.5), 20% PEG 3350,
25% ethylene glycol, and 10% isopropanol at 4C. It forms in spacethrombin cleavage, Q Sepharose (Phamacia), and Superdex 200
(Phamacia) columns. The PDE4D2 protein has purity greater than group P212121, with cell dimensions of a  99.8, b  111.5, and c 
160.0 A˚. The diffraction data were collected on beamline 14C of95% as shown by SDS-PAGE. A typical purification yielded over
100 mg PDE4D2 from a 2 liter cell culture. APS at the Argonne National Laboratory (Table 1) and processed
with the program HKL (Otwinowski and Minor, 1997).
Crystallization and Data Collection
The crystals were obtained by vapor diffusion with 15 mg/ml Structure Determination
The crystals of PDE4D2 in complex with roliprams contain a tetramerPDE4D2 in a storage buffer of 50 mM NaCl, 20 mM Tris-HCl (pH
7.5), 1 mM -mercaptoethanol, and 1 mM EDTA. The crystals of the in the crystallographic asymmetric unit. The structure of PDE4D2-
rolipram was solved by the molecular replacement program AMoRecatalytic domain of PDE4D2 (amino acids 79–438) in complex with
(R)-rolipram were grown against a well buffer of 0.1 M HEPES (pH (Navaza and Saludjian, 1997), with the catalytic domain of PDE4B
as the initial model (Xu et al., 2000) and a preliminary 2.8 A˚ resolution7.5), 20% PEG 3350, 30% ethylene glycol, 10% isopropanol, and
5% glycerol at 4C. It forms in space group P212121, with cell dimen- data set that was collected on beamline X12C at the Brookhaven
National Lab. The translation search of a monomer yielded a correla-sions of a  99.3, b  112.5, and c  160.9 A˚. The diffraction
data were collected on beamline X25 at the Brookhaven National tion coefficient of 0.20 and an R factor of 0.51 for 10,784 reflections
Structure
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between 4 and 8 A˚ resolution. The translational search for the re- a central role for cyclic AMP phosphodiesterases. Semin. Cell Dev.
Biol. 9, 161–167.maining molecules under the fixed orientation of the first molecule
produced three solutions with correlation coefficients of 0.31, 0.33, Houslay, M.D., and Milligan, G. (1997). Tailoring cAMP-signalling
and 0.23 and R factors of 0.48, 0.47, and 0.51, respectively. The responses through isoform multiplicity. Trends Biochem. Sci. 22,
tetramer of PDE4D-rolipram was optimized by rigid-body refinement 217–224.
with CNS (Bru¨nger et al., 1998). The electron density map was im-
Houslay, M.D., Sullivan, M., and Bolger, G.B. (1998). The multien-
proved by the density modification package of CCP4 (CCP4, 1994).
zyme PDE4 cyclic adenosine monophosphate-specific phosphodi-
The atomic model was rebuilt with the program O (Jones et al.,
esterase family: intracellular targeting, regulation, and selective inhi-
1991) and refined with CNS (Table 1).
bition by compounds exerting anti-inflammatory and antidepressant
actions. Adv. Pharmocol. 44, 225–343.
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